[{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"National Heart, Lung, and Blood Institute | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ramipril","moa":"Angiotensin-converting enzyme","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ National Heart, Lung, and Blood Institute | AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"University of Alabama at Birmingham \/ National Heart, Lung, and Blood Institute | AstraZeneca"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDONESIA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"DLBS1449","moa":"Blood glucose level","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dexa Medica \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Dexa Medica \/ Undisclosed"},{"orgOrder":0,"company":"Prisma Health-Midlands","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"DGAT||steroids (androgens","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Prisma Health-Midlands","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Prisma Health-Midlands \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Prisma Health-Midlands \/ Undisclosed"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDONESIA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"DLBS1033","moa":"Fibrinolytic protein","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dexa Medica \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Dexa Medica \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Supaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Supaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Supaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","highestDevelopmentStatusID":"9","companyTruncated":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"},{"orgOrder":0,"company":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","sponsor":"Shanghai 6th People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Supaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ Shanghai 6th People's Hospital","highestDevelopmentStatusID":"9","companyTruncated":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ Shanghai 6th People's Hospital"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Beta Bionics | Zealand Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2019","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Beta Bionics | Zealand Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Massachusetts General Hospital \/ Beta Bionics | Zealand Pharma"},{"orgOrder":0,"company":"University Hospital, Caen","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"University Hospital, Caen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University Hospital, Caen \/ Eli Lilly","highestDevelopmentStatusID":"9","companyTruncated":"University Hospital, Caen \/ Eli Lilly"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de Besancon","sponsor":"AstraZeneca | Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Centre Hospitalier Universitaire de Besancon","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Hospitalier Universitaire de Besancon \/ AstraZeneca | Eli Lilly","highestDevelopmentStatusID":"9","companyTruncated":"Centre Hospitalier Universitaire de Besancon \/ AstraZeneca | Eli Lilly"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"NETHERLANDS","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radboud University Medical Center \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Radboud University Medical Center \/ AstraZeneca"},{"orgOrder":0,"company":"University Hospital Gentofte, Copenhagen","sponsor":"Novo Nordisk | University of Copenhagen","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"University Hospital Gentofte, Copenhagen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University Hospital Gentofte, Copenhagen \/ Novo Nordisk | University of Copenhagen","highestDevelopmentStatusID":"9","companyTruncated":"University Hospital Gentofte, Copenhagen \/ Novo Nordisk | University of Copenhagen"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Tongji Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Pegylated Somatropin","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Tongji Hospital","highestDevelopmentStatusID":"9","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Tongji Hospital"},{"orgOrder":0,"company":"Transdermal Delivery Solutions Corp","sponsor":"Langford Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Transdermal Delivery Solutions Corp","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transdermal Delivery Solutions Corp \/ Langford Research Institute","highestDevelopmentStatusID":"9","companyTruncated":"Transdermal Delivery Solutions Corp \/ Langford Research Institute"},{"orgOrder":0,"company":"Jaeb Center for Health Research","sponsor":"Mannkind","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Jaeb Center for Health Research","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jaeb Center for Health Research \/ Mannkind","highestDevelopmentStatusID":"9","companyTruncated":"Jaeb Center for Health Research \/ Mannkind"},{"orgOrder":0,"company":"Biocon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Insulin Tregopil","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biocon \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Biocon \/ Undisclosed"},{"orgOrder":0,"company":"Biocon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Insulin Tregopil","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biocon \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Biocon \/ Undisclosed"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"Juvenile Diabetes Research Foundation | Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of British Columbia \/ Juvenile Diabetes Research Foundation | Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"9","companyTruncated":"University of British Columbia \/ Juvenile Diabetes Research Foundation | Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"NovaMed Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"PAKISTAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Alpha Lipoic Acid","moa":"Lipoyl amidotransferase LIPT1, mitochondrial; Sodium-dependent multivitamin transporter; Lipoyl synthase, mitochondrial","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"NovaMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NovaMed Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"NovaMed Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Niagen Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Niagen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Niagen Bioscience \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Niagen Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Han Xu","sponsor":"UnitedHealthcare","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Han Xu","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Han Xu \/ UnitedHealthcare","highestDevelopmentStatusID":"9","companyTruncated":"Han Xu \/ UnitedHealthcare"},{"orgOrder":0,"company":"UConn Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Amino Acid","year":"2024","type":"Inapplicable","leadProduct":"Levothyroxine Sodium","moa":"Thyroid hormone receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"UConn Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UConn Health \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"UConn Health \/ Undisclosed"},{"orgOrder":0,"company":"Throne Biotechnologies","sponsor":"Hackensack Meridian Health","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Cord Blood Stem Cell","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Throne Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Throne Biotechnologies \/ Hackensack Meridian Health","highestDevelopmentStatusID":"9","companyTruncated":"Throne Biotechnologies \/ Hackensack Meridian Health"},{"orgOrder":0,"company":"Throne Biotechnologies","sponsor":"Chinese PLA General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Cord Blood Stem Cell","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Throne Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Throne Biotechnologies \/ Chinese PLA General Hospital","highestDevelopmentStatusID":"9","companyTruncated":"Throne Biotechnologies \/ Chinese PLA General Hospital"},{"orgOrder":0,"company":"Global Cell Med","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"MALAYSIA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Adult Bone Marrow Stem Cell","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Global Cell Med","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Global Cell Med \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Global Cell Med \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AGN-282176","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Kexing Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"GB08","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Kexing Biopharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kexing Biopharm \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Kexing Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Intralipid","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gabrail Cancer Center Research \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"9","companyTruncated":"Gabrail Cancer Center Research \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Polysan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"RUSSIA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Reamberin","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Polysan","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Polysan \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Polysan \/ Undisclosed"},{"orgOrder":0,"company":"Catalysis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Spermotrend","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Catalysis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Catalysis \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Catalysis \/ Undisclosed"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Partnership","leadProduct":"TOTUM\u202263","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Valbiotis","sponsor":"INAF","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"TOTUM\u202263","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ INAF","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ INAF"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"TOTUM\u202263","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Undisclosed"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"TOTUM\u202263","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Undisclosed"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"TOTUM\u202263","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Biofortis M\u00e9rieux Nutriscience | Institut Pasteur de Lille","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Totum-63","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Biofortis M\u00e9rieux Nutriscience | Institut Pasteur de Lille","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Biofortis M\u00e9rieux Nutriscience | Institut Pasteur de Lille"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Biofortis M\u00e9rieux Nutriscience","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Totum-63","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Biofortis M\u00e9rieux Nutriscience","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Biofortis M\u00e9rieux Nutriscience"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Laval University | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | Valbiotis Canada inc.","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Totum-63","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Laval University | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | Valbiotis Canada inc.","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Laval University | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | Valbiotis Canada inc."}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : AGN-282176 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Hypothyroidism.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 03, 2024

                          Lead Product(s) : AGN-282176

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          02

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : GB08 is a Other Large Molecule drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Dwarfism, Pituitary.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 17, 2025

                          Lead Product(s) : GB08

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Han Xu

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Han Xu

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Dapagliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 24, 2025

                          Lead Product(s) : Dapagliflozin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : UnitedHealthcare

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Reamberin is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Diabetic Ketoacidosis.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          May 02, 2025

                          Lead Product(s) : Reamberin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          UConn Health

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          UConn Health

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Levothyroxine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Hypothyroidism.

                          Product Name : Undisclosed

                          Product Type : Amino Acid

                          Upfront Cash : Inapplicable

                          December 12, 2024

                          Lead Product(s) : Levothyroxine Sodium

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Jaeb Center for Health Research

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Jaeb Center for Health Research

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Insulin is a Hormone drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Diabetes, Gestational.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          August 02, 2024

                          Lead Product(s) : Insulin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Mannkind

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Through the acquisition, AstraZeneca leverages the AZP-3601 (neboparatide), peptide agonist of the PTH1 receptor. Currently, being evaluated for the treatment of Chronic Hypoparathyroidism.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : $800.0 million

                          July 15, 2024

                          Lead Product(s) : Eneboparatide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : AstraZeneca

                          Deal Size : $1,050.0 million

                          Deal Type : Acquisition

                          blank

                          08

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : TOTUM•63 is a unique and patented combination of 5 plant extracts that targets the pathophysiological mechanisms of type 2 diabetes. TOTUM•63 benefits from intellectual property validated by patents in the world's leading markets.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          May 22, 2023

                          Lead Product(s) : TOTUM•63

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Nestle Health Sciences SA

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : TOTUM-63 is a unique and patented combination of 5 plant extracts that targets the pathophysiological mechanisms of type 2 diabetes, has already been shown to be safe and effective in healthy volunteers in a Phase I/II clinical study.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          April 29, 2022

                          Lead Product(s) : TOTUM•63

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : INAF

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Prisma Health-Midlands

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Prisma Health-Midlands

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Lovaza is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Diabetes Mellitus.

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          March 16, 2022

                          Lead Product(s) : Omega-3-Acid Ethyl Esters 90

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank